SGMT

Sagimet Biosciences Inc. - Series A Common Stock (SGMT)

About Sagimet Biosciences Inc. - Series A Common Stock (SGMT)

Sagimet Biosciences, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel therapeutics for the treatment of infectious diseases. Its lead drug candidate, denifanstat, is an oral, once-daily pill and selective fatty acid synthase (FASN) inhibitor in development for the treatment of nonalcoholic steatohepatitis (NASH). The company was founded by Urs F. Greber, Ari Helenius, and Lucas Pelkmans on December 19, 2006 and is headquartered in San Mateo, CA.

Details

Daily high

$3.23

Daily low

$3.00

Price at open

$3.12

52 Week High

$7.38

52 Week Low

$1.73

Market cap

101.4M

Dividend yield

0.00%

Volume

474,111

Avg. volume

762,186

P/E ratio

-2.19

Sagimet Biosciences Inc. - Series A Common Stock News